- Home
- NZF vs HCM Comparison
NZF vs HCM Comparison
Compare NZF & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NZF | HCM |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | NZF | HCM |
|---|---|---|
| Price | $12.63 | $14.10 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | ★ 476.5K | 20.1K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.37 |
| Revenue Next Year | N/A | $17.50 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.98 | $11.51 |
| 52 Week High | $13.22 | $19.50 |
Technical Indicators
Market Signals| Indicator | NZF | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 46.68 |
| Support Level | $12.30 | $13.09 |
| Resistance Level | $12.83 | $14.80 |
| Average True Range (ATR) | 0.14 | 0.42 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 16.00 | 53.81 |
Price Performance
Historical ComparisonAbout NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.